|
|
News Breaks | | | | October 1, 2012 | | 08:03 EDT |  | CLSN | Celsion provides clinical update of Phase I/II DIGNITY trial of ThermoDox
Celsion Corporation announced the presentation of Phase I results from the company's Phase I/II DIGNITY study of ThermoDox in Breast Cancer Recurrences at the Chest Wall at the ESMO 2012 Congress, the annual conference for the European Society of Medical Oncology held in Vienna, Austria September 28 to October 2, 2012. The presentation, titled "Breast Cancer Recurrences at the Chest Wall When Standard Treatments Have Failed: Lyso-thermosensitive liposomal doxorubicin + Mild Local Hyperthermia," was delivered by Professor Hope S. Rugo, MD, from the UCSF School of Medicine, and provided a clinical update of the Phase I/II DIGNITY trial studying ThermoDox for breast cancer. | |
|
News For CLSN From The Last 14 Days Check below for free stories on CLSN the last two weeks. |
|
|
| May 22, 2013 | | 08:03 EDT | | CLSN | Celsion announces issurance of more patents covering ThermoDox technologies
Celsion announced that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has now been granted in the four largest markets for liver cancer globally: China, Japan, South Korea and most recently Taiwan. Celsion holds an exclusive license agreement with Duke University for its temperature sensitive liposome technology which covers the ThermoDox formulation. Celsion's newly issued patents pertain specifically to methods of storing stabilized, temperature-sensitive liposomal formulations and will assist in the protection of global rights by extending the overall term of the ThermoDox patent portfolio to August 2026. | | | May 16, 2013 | | 07:28 EDT |  | CLSN | I/O Central to host a conference
 Subscribe for More Information | | | May 9, 2013 | | 08:06 EDT |  | CLSN | Celsion reports Q1 EPS (12c), one estimate (16c)
Reports Q1 revenue $125,000, consensus $190,000 | |
|
|
|
|
|
|
